HPV-Risk Assay / QIAscreen
Primary cervical cancer screening (HPV detection)
ApprovedCommercial
Key Facts
Indication
Primary cervical cancer screening (HPV detection)
Phase
Approved
Status
Commercial
Company
About Self-screen
Self-screen is a private, commercial-stage diagnostics company based in Amsterdam, specializing in molecular tests for cervical cancer prevention. Its product portfolio includes the HPV-Risk Assay for primary screening and the PreCursor-M+ methylation test for triage of HPV-positive women, aiming to reduce overtreatment. The company's strategy leverages translational science to create best-in-class assays that support global screening programs, including those utilizing self-sampling. With its products on the market and a focus on epigenetic biomarkers, Self-screen is positioned in the growing molecular diagnostics segment for HPV-related cancers.
View full company profile